Delcath Systems Closes $9.5 Million Private Placement
August 20, 2019 08:00 ET
|
Delcath Systems, Inc.
Bringing total financial amount raised since July 2019 to $29.5M Cash runway past top-line results in 1H2020 with NDA submission anticipated by end of 2020 Recapitalization provides possible...
Delcath Systems Announces $9.5 Million Private Placement
August 15, 2019 18:02 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH)) today announced that it has entered into a definitive agreement for...
Delcath Enhances Board of Directors With Appointment of Commercial Leader, John R. Sylvester
July 29, 2019 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...
Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging
July 22, 2019 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, July 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Systems Closes $20 Million Private Placement
July 17, 2019 16:05 ET
|
Delcath Systems, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCPK: DCTH) has closed on its previously announced private placement with gross...
Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019
April 16, 2019 08:15 ET
|
Delcath Systems, Inc.
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
February 28, 2019 10:38 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
February 08, 2019 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification
December 18, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
October 15, 2018 10:57 ET
|
Delcath Systems, Inc.
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Delcath...